Anaplastic oligodendroglial tumors

Handbook of Clinical Neurology

Volumn 105, Issue , 2012, Pages 467-484

  van den Bent, M J ^a   Bromberg, J E C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855522024     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53502-3.00003-3     Document Type: Chapter

References (104)

1. Abrey L.E., Childs B.H., Paleologos N., et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro-oncol 2006, 8:183-188.
2. Alonso M.E., Bello M.J., Gonzalez-Gomez P., et al. Aberrant promotor methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 2003, 144:134-142.
3. Balss J., Meyer J., Mueller W., et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008, 116:597-602.
4. Barker F.G., Chang C.H., Huhn S.L., et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997, 80:936-941.
5. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
6. Berger M.S., Deliganis A.V., Dobbins J., et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994, 74:1784-1791.
7. Biemond-ter Stege E., Kros J.M., de Bruin H.G., et al. Treatment of low grade oligodendroglial tumors with PCV chemotherapy. Cancer 2005, 103:802-809.
8. Bigner S.H., Matthews M.R., Rasheed B.K.A., et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999, 155:375-386.
9. Brada M., Viviers L., Abson C., et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003, 14:1715-1721.
10. Brada M., Gabe R., Stenning S., et al. A randomized trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (Medical Research Council trial BR12). Neuro-oncol 2008, 10:1067. (abstract).
11. 6 -methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006, 24:4746-4753.
12. Buckner J.C., Gesme D., O'Fallon J.R., et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003, 21:251-255.
13. Bullard D.E., Rawlings C.E., Philllips B., et al. Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 1987, 60:2179-2188.
14. Cairncross G., Macdonald D., Ludwin S., et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994, 12:2013-2021.
15. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473-1479.
16. Cairncross J.G., Berkey B., Shaw E., et al. Phase III trial of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): an intergroup trial by the RTOG, NCCTG, SWOG, NCI CTG and ECOG. J Clin Oncol 2006, 24:2707-2714.
17. Celli P., Nofrone I., Palma L., et al. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994, 35:1018-1035.
18. Chamberlain M.C., Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 2009, 115:1734-1743.
19. Chinot O., Honore S., Dufour H., et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001, 19:2449-2455.
20. Constanza A., Borgogne M., Nobile M., et al. Temozolomide in recurrent oligodendroglioma: a phase II study. Neuro-oncol 2001, 3:S66. (abstract).
21. Coons S.W., Johnson P.C., Scheithauer B.W., et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997, 79:1381-1391.
22. Dehais C., Laigle-Donadey F., Marie Y., et al. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 2006, 107:1891-1897.
23. Dong S.M., Pang J.C., Poon W.S., et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001, 60:808-816.
24. Ducray F., Idbaih A., de Reynies A., et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008, 7:41.
25. Ducray F., Criniere E., Idbaih A., et al. α-Internexin expression identifies 1p19q codeleted gliomas. Neurology 2009, 72:156-161.
26. Fallon K.B., Palmer C.A., Roth K.A., et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004, 63:314-322.
27. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
28. Gan H.K., Rosenthal M.A., Dowling A., et al. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neuro-oncol 2010, 12:500-507.
29. Gannett D.E., Wisbeck W.M., Silbergeld D.L., et al. The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 1994, 30:567-573.
30. Giammarile F., Cinotti L.E., Jouvet A., et al. High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neurooncol 2004, 68:263-274.
31. Griffin C.A., Burger P., Morsberger L., et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006, 65:988-994.
32. Hartmann C., Meyer J., Balss J., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009, 118:469-474.
33. Hegi M.E., Diserens A.-C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
34. Hoang-Xuan K., Huguet S., Mokhtari K., et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2002, 57:1278-1281.
35. Hoang-Xuan K., Capelle L., Kujas M., et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004, 22:3133-3138.
36. Idbaih A., Marie Y., Pierron G., et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 2005, 58:483-487.
37. Idbaih A., Criniere E., Marie Y., et al. Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. Neuro-oncol 2008, 10:540-547.
38. Ino Y., Betensky R.A., Zlatescu M.C., et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001, 7:839-845.
39. Jenkinson M.D., Smith T.S., Joyce K., et al. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005, 64:2085-2089.
40. Jenkinson M.D., du Plessis D.G., Smith T.S., et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006, 129:1884-1891.
41. Jenkins R.B., Blair H., Ballman K.V., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006, 66:9852-9861.
42. Jeuken J.W.M., Sprenger S.H.E., Wesseling P., et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 1999, 58:606-612.
43. Karim A.B.M.F., Maat B., Hatlevoll R., et al. A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 2284. Int J Radiation Oncol Biol Phys 1996, 36:549-556.
44. Kim Y.H., Nobusawa S., Mittelbronn M., et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010, 177:2708-2714.
45. Klein M., Heimans J.J., Aaronson N.K., et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet 2002, 360:1361-1368.
46. Klein M., Fagel S., Taphoorn M.J.B., et al. Neurocognitive functioning in long-term low-grade glioma survivors: a six year follow-up study. Neuro-oncol 2006, 8:302. (abstract).
47. Kloosterhof N.K., Bralten L.B., Dubbink H.J., et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. Lancet Oncol 2011, 12:83-91.
48. Kouwenhoven M.C., Kros J.M., French P.J., et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 2006, 42:2499-2503.
49. Kros J.M., Troost D., Van Eden C.G., et al. Oligodendroglioma: a comparison of two grading systems. Cancer 1988, 61:2251-2259.
50. Krouwer H.G.J., van Duinen S.G., Kamphorst W., et al. Oligoastrocytomas: a clinicopathological study of 52 cases. J Neurooncol 1997, 33:223-238.
51. Lee Y., van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. Am J Radiol 1989, 152:361-369.
52. Leighton C., Fisher B., Bauman G., et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and the timing of radiation. J Clin Oncol 1997, 15:1294-1301.
53. Maintz D., Fiedler K., Koopmann J., et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997, 56:1098-1104.
54. Mason W.P., DeAngelis L.M. Procarbazine, CCNU, vincristine (PCV) chemotherapy (CT) for benign oligodendroglioma. Neurology 1994, 44:A262-A263.
55. Mason W.P., Krol G.S., DeAngelis L.M. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996, 46:203-207.
56. McDonald J.M., See S.J., Tremont I.W., et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 2005, 104:1468-1477.
57. Megyesi J.F., Kachur E., Lee D.H., et al. Imaging correlates of molecular signatures in oligodendroglioma. Clin Cancer Res 2004, 10:4303-4306.
58. Miller C.R., Dunham C.P., Scheithauer B.W., et al. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006, 24:5419-5426.
59. Mokhtari K., Paris S., Guirre-Cruz L., et al. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol 2005, 31:62-69.
60. Möllemann M., Wolter M., Felsberg J., et al. Frequent promotor hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2004, 113:379-385.
61. Mueller W., Hartmann C., Hoffmann A., et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002, 161:313-319.
62. Nijjar T.S., Simpson W.J., Gadalla T., et al. Oligodendroglioma. The Princess Margaret Hospital Experience (1958-1984). Cancer 1993, 71:4002-4006.
63. Noushmehr H., Weisenberger D.J., Diefes K., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
64. 6 methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage. Can J Neurol Sci 1995, 22:111-115.
65. Peereboom D., Brewer C., Schiff D., et al. Dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. Neuro-oncol 2006, 8:448. (abstract).
66. Pignatti F., van den Bent M.J., Curran D., et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002, 20:2076-2084.
67. Reifenberger G., Kros J.M., Burger P., et al. Oligodendroglioma. World Health Organization Classification of Tumours 2000, 55-70. IARC Press, Lyons, Pathology and Genetics of Tumours of the Nervous System. P. Kleihues, W.K. Cavenee (Eds.).
68. Reifenberger J., Reifenberger G., Liu L., et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994, 145:1175-1190.
69. 11 C-methionine and survival in patients with low-grade gliomas. Cancer 2001, 92:1541-1549.
70. Rousseau A., Nutt C.L., Betensky R.A., et al. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol 2006, 65:1149-1156.
71. Sasaki H., Zlatescu M.C., Betensky R.A., et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma" J Neuropathol Exp Neurol 2002, 61:58-63.
72. Shaw E.G., Scheithauer B.W., O'Fallon J.R., et al. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992, 76:428-434.
73. Shaw E.G., Scheithauer B.W., O'Fallon J.R. Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 1997, 31:273-278.
74. Shaw E., Arusell R.M., Scheithauer B., et al. A prospective randomized trial of low versus high dose radiation in adults with a supratentorial low grade glioma: initial report of a NCCTG-RTOG-ECOG study. J Clin Oncol 2002, 20:2267-2276.
75. Smith J.S., Alderete B., Minn Y., et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999, 18:4144-4152.
76. Smith J.S., Perry A., Borell T.J., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol 2000, 18:636-645.
77. Soffietti R., Ruda R., Bradac G.B., et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998, 43:1066-1073.
78. Soichi O., Masanori N., Hideo T., et al. Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. Neurosurgery 2007, 60:707-714.
79. Spampinato M.V., Smith J.K., Kwock L., et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007, 188:204-212.
80. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
81. Taillibert S., Vincent L.A., Granger B., et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009, 72:1601-1606.
82. Taliansky-Aronov A., Bokstein F., Lavon I., et al. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 2006, 79:153-157.
83. Tews B., Roerig P., Hartmann C., et al. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Oncogene 2007, 26:5010-5016.
84. Triebels V., Taphoorn M.J.B., Brandes A.A., et al. Response to 2nd line PCV chemotherapy in recurrent oligodendroglioma after 1st line temozolomide. Neurology 2004, 63:904-906.
85. van den Bent M.J. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 2010, 120:297-304.
86. van den Bent M.J., Kros J.M., Heimans J.J., et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology 1998, 51:1140-1145.
87. van den Bent M.J., Keime-Guibert F., Brandes A.A., et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001, 57:340-342.
88. van den Bent M.J., Chinot O.-L., Cairncross J.G. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncol 2003, 5:128-138.
89. van den Bent M.J., Looijenga L.H.J., Langenberg K., et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003, 97:1276-1284.
90. van den Bent M.J., Taphoorn M.J., Brandes A.A., et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma: the European Organisation for Research and Treatment of Cancer Brain Tumor Group study 26971. J Clin Oncol 2003, 21:2525-2528.
91. van den Bent M.J., Brandes A.A., van Oosterom A.T., et al. Multicentre phase II study of imatinib mesylate (Gleevec) in patients with recurrent glioblastoma: an EORTC NDDG/BTG intergroup study. Neuro-oncol 2004, 6:383. (abstract).
92. van den Bent M.J., Afra D., De Witte O., et al. Long term results of EORTC study 22845: a randomized trial on the efficacy of early versus delayed radiation therapy of low-grade astrocytoma and oligodendroglioma in the adult. Lancet 2005, 366:985-990.
93. van den Bent M.J., Carpentier A.F., Brandes A.A., et al. Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol 2006, 24:2715-2722.
94. van den Bent M.J., Dubbink H.J., Sanson M., et al. MGMT Promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009, 27:5881-5886.
95. van den Bent M.J., Dubbink H.J., Marie Y., et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010, 16:1597-1604.
96. Vogelbaum M.A., Berkey B., Peereboom D., et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro-oncol 2009, 11:167-175.
97. Walker C., du Plessis D.G., Joyce K.A., et al. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 2005, 57:855-865.
98. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333-343.
99. Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
100. Wallner K.E., Gonzales M., Sheline G.E. Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 1988, 68:684-688.
101. Watanabe T., Nakamura M., Kros J.M., et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 2002, 103:267-275.
102. Watanabe T., Nobusawa S., Kleihues P., et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174:1149-1153.
103. Wick W., Hartmann C., Engel C., et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009, 27:5874-5880.
104. Zlatescu M.C., Tehrani Yazdi A., Sasaki H., et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001, 18:6713-6715.